Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

HIV-1-infection Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

11 recruiting trials for HIV-1-infection. Eligibility criteria explained in plain English.

TrialFinderData lists 11 HIV-1-infection clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 33% (2 studies); the largest phase groups are Phase 2: 2, Phase 1 / Phase 2: 1, Phase 3: 1, Phase 4: 1.

Research is led by Massachusetts General Hospital (2), Fondazione ICONA (1), National Institute of Allergy and Infectious Diseases (NIAID) (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Placebo (drug, 4 trials), followed by MVA.tHIVconsv4, BNT351.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
11
Total Trials
11
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Track HIV-1-infection trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 2NCT06843902

Improving Coronary Vascular Health in Women

Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of...

Sponsor: Massachusetts General HospitalEnrolling: 801 location
RECRUITINGPhase 2NCT06554717

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

People with HIV experience earlier impairments in physical function compared to people in the general population. They also exhibit an earlier presentation and more rapid...

Sponsor: Massachusetts General HospitalEnrolling: 1002 locations
RECRUITINGNCT07186244

Prevention ICONA Dedicated Ensemble

Despite significant advances in HIV treatment, transmission remains a public health concern. In 2022, there were 1.3 million new HIV infections worldwide and 1,888 new diagnoses...

Sponsor: Fondazione ICONAEnrolling: 500020 locations
RECRUITINGPhase 1 / Phase 2NCT06071767

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute...

The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus ChAdOx1- and poxvirus modified vaccinia...

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)Enrolling: 3612 locations
RECRUITINGNCT07293559

Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States

IMPAACT 2046/UPLIFT (Understanding Practices of Lactation and Infant Feeding decisions Together with women with HIV) is a multi-site, mixed-methods, observational cohort study....

Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials GroupEnrolling: 115011 locations
RECRUITINGNCT06762054

Investigating the Optimal Management of Dolutegravir Resistance

The goal of this study is to address the gap in published data on viral suppression among people meeting the criteria for virologic failure on dolutegravir (DTG)-based ART...

Sponsor: University of NairobiEnrolling: 66009 locations
RECRUITINGPhase 3NCT04892654

Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch

Combination antiretroviral therapy (cART) HIV treatments are associated with increased quality of life, and a normalisation of life expectancy in people living with HIV. However,...

Sponsor: Chelsea and Westminster NHS Foundation TrustEnrolling: 1503 locations
RECRUITINGPhase 4NCT06602622

Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI

Patients who developed metabolic syndrome after initiation of HIV treatment or with antiretroviral therapy (ART) for at least 36 months, treated with second generation integrase...

Sponsor: Instituto Mexicano del Seguro SocialEnrolling: 1082 locations
RECRUITINGNCT04174755

Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV

The prevalence of obesity is rising worldwide, both in low- and high-income countries, including people with HIV (PWH). Semaglutide's efficacy in achieving weight loss in obese...

Sponsor: University College DublinEnrolling: 801 location
RECRUITINGPhase 1NCT07392372

A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and...

This study will test the safety and blood levels of the antibody BNT351 in people living without and with human immunodeficiency virus (HIV). This study will also test the...

Sponsor: BioNTech SEEnrolling: 676 locations
RECRUITINGNCT07563309

A Study to Evaluate Performance, Usability, and Contrived Result Interpretation of TruPlex HIV/HepB/Syphilis Rapid Test

The objectives of this study are as follows: To evaluate the clinical performance of the TruPlex test using capillary blood, EDTA whole blood, EDTA plasma, and SST serum samples...

Sponsor: bioLytical LaboratoriesEnrolling: 10003 locations

Frequently Asked Questions

There are currently 11 clinical trials for HIV-1-infection, with 11 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for HIV-1-infection, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for HIV-1-infection, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.